{
  "docId": "019de074-559c-76fa-9457-a7d91e9a06c5",
  "docSlug": "15199f0b497c4ef204a0760da27401b3",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 54 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 50,
  "pageCount": 54,
  "prevPage": 49,
  "nextPage": 51,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a comparative framework to highlight the competitive advantage of the proposed product over the incumbent Depo-Provera.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-559c-76fa-9457-a7d91e9a06c5/50",
  "deckHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5",
  "deckJsonHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5.json",
  "deckAnchorHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5#slide-50",
  "components": [
    {
      "bbox": {
        "h": 0.025,
        "w": 0.761,
        "x": 0.085,
        "y": 0.343
      },
      "kind": "callout",
      "text": "~65M women in U.S. are in the reproductive health and contraception market segment¹",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12166947-8ddf-436a-bb37-938ca0f8bbc0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.155,
        "w": 0.886,
        "x": 0.057,
        "y": 0.475
      },
      "kind": "list",
      "text": "Some of the limitations with DEPO-PROVERA include the following:²,³ 1. Requires an injection 4 times per year. 2. Unpredictable return to fertility. 3. Research suggests that Depo-Provera and Depo-SubQ Provera 104 might cause a loss of bone mineral density.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97f5ce50-505f-4762-af95-43d546eb22ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.845,
        "x": 0.043,
        "y": 0.241
      },
      "kind": "paragraph",
      "text": "Novel 6 & 12-month injectable formulations of etonogestrel being developed as a longer-acting, reversible method of contraception with a more predictable return to fertility. There are currently no FDA approved injectable contraceptives available indicated for 6-12 months protection.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "087d33ee-16dc-4c85-afda-08f2fd770dfe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.065,
        "w": 0.886,
        "x": 0.057,
        "y": 0.401
      },
      "kind": "paragraph",
      "text": "The only approved injectable contraceptive product in the U.S. is DEPO-PROVERA CI (medroxyprogesterone acetate) injectable suspension, which is indicated as every 3 months (13 weeks) administered by deep, intramuscular injection in the gluteal or deltoid muscle.²",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43c77d14-1ecb-4774-8c24-4b6b5e203314",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.085,
        "w": 0.886,
        "x": 0.057,
        "y": 0.663
      },
      "kind": "paragraph",
      "text": "The target product profile potential for ADARE204/214 are 6- and 12- month formulations, minimizing the number of injections required per year, and with a predictable return to fertility relative to the 6- or 12- month contraceptive window. Active is etonogestrel which does not have same black box warning regarding bone loss as medoxyprogesterone acetate.⁴",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d37871c2-a96e-4624-b916-681eb6dd202a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.96,
        "x": 0.02,
        "y": 0.785
      },
      "kind": "source-note",
      "text": "*505(b)(2) candidate^ ^Anticipated regulatory pathway. Daré has not had any communications with the FDA regarding the specific marketing approval requirements for ADARE 204/214 1 - CDC National Survey for Family Growth, 2013-2015 dataset, cdc.gov. 2 - https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020246s036lbl.pdf 3 - https://www.mayoclinic.org/tests-procedures/depo-provera/about/pac-20392204#:~:text=Among%20the%20things%20to%20consider,birth%20control%20method%20of%20your 4 - https://www.organon.com/product/usa/pi_circulars/n/nexplanon/nexplanon_pi.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4151b827-b898-4053-8f34-2dd9c60b6c0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.032,
        "w": 0.198,
        "x": 0.401,
        "y": 0.163
      },
      "kind": "title",
      "text": "ADARE 204/214*",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ac5c872-6c98-43a2-ac4d-a296ea0c6552",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "4ef8187a-137d-4513-b66f-5538c2e420c8",
      "evidence": "Contrasts current limitations of Depo-Provera with the proposed benefits of ADARE 204/214.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 54,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "2cf418f8-2568-4e9a-bf9d-f55bdd0bfb9e",
      "evidence": "The deck implies that inaction in women's health has significant consequences",
      "position": 0,
      "objective": "What is the cost of inaction in women's health?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}